Skip to content
Annika Bansal – Lifestyle
Author:
BioInvent International
BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026
October 18, 2026
BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research
October 15, 2026
BioInvent International AB Announces that its CFO will Retire in 2027
October 12, 2026
Lupus Research Alliance Awards More Than $2 Million to Study the Power of Lifestyle Interventions
August 29, 2026
BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research
August 20, 2026
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
August 7, 2026
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
July 28, 2026
BioInvent’s BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
July 17, 2026
BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
June 11, 2026
BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
June 11, 2026
1
2
Next Page
→